Eli Lilly and Co

자세한 내용은 Eli Lilly and Co 회사

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

회사 정보

종목 코드 LLY

회사 이름Eli Lilly and Co

상장일Jul 09, 1970

CEOMr. David A. (Dave) Ricks

직원 수47000

유형Ordinary Share

회계 연도 종료Jul 09

주소Lilly Corporate Ctr

도시INDIANAPOLIS

증권 거래소NYSE Consolidated

국가United States of America

우편 번호46285

전화13172762000

웹사이트https://www.lilly.com/

종목 코드 LLY

상장일Jul 09, 1970

CEOMr. David A. (Dave) Ricks

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+13.18%

Mr. J. Erik Fyrwald

Independent Director

72.75K

+0.02%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+20.12%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.75K

+4.13%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

27.51K

-4.35%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-41.06%

Dr. Katherine Baicker, Ph.D.

Independent Director

23.16K

+0.62%

Mr. Diogo Rau

Executive Vice President, Chief Information and Digital Officer

19.72K

+77.63%

Mr. Lucas E. Montarce

Chief Financial Officer, Executive Vice President

13.97K

+26.18%

Mr. Eric Dozier

Executive Vice President - Human Resources and Diversity

9.84K

+15.72%

이름

이름/직위

직위

주식 보유

변동

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+13.18%

Mr. J. Erik Fyrwald

Independent Director

72.75K

+0.02%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+20.12%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.75K

+4.13%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

27.51K

-4.35%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-41.06%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Diabetes-Mounjaro

3.84B

30.18%

Diabetes-Zepbound

2.31B

18.16%

Oncology-Verzenio

1.16B

9.10%

Diabetes-Trulicity

1.10B

8.60%

Diabetes-Jardiance

1.01B

7.97%

Other

3.31B

25.98%

지역별USD

이름

수익

비율

U.S.

8.49B

66.70%

Europe

2.39B

18.77%

Other foreign countries

997.40M

7.84%

China

450.80M

3.54%

Japan

402.20M

3.16%

사업별

지역별

사업별USD

이름

수익

비율

Diabetes-Mounjaro

3.84B

30.18%

Diabetes-Zepbound

2.31B

18.16%

Oncology-Verzenio

1.16B

9.10%

Diabetes-Trulicity

1.10B

8.60%

Diabetes-Jardiance

1.01B

7.97%

Other

3.31B

25.98%

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Lilly Endowment, Inc.

10.12%

The Vanguard Group, Inc.

8.46%

PNC Investments LLC

5.40%

BlackRock Institutional Trust Company, N.A.

4.36%

State Street Global Advisors (US)

3.64%

Other

68.03%

주주

비율

Lilly Endowment, Inc.

10.12%

The Vanguard Group, Inc.

8.46%

PNC Investments LLC

5.40%

BlackRock Institutional Trust Company, N.A.

4.36%

State Street Global Advisors (US)

3.64%

Other

68.03%

주주 유형

주주

비율

Investment Advisor

46.30%

Investment Advisor/Hedge Fund

18.41%

Foundation

10.12%

Research Firm

1.93%

Pension Fund

1.81%

Bank and Trust

1.80%

Insurance Company

1.49%

Sovereign Wealth Fund

1.24%

Hedge Fund

0.91%

Other

15.99%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

5717

798.76M

84.28%

+2.87M

2025Q1

5710

800.38M

84.44%

+5.04M

2024Q4

5528

795.43M

83.87%

+627.51K

2024Q3

5177

793.57M

83.49%

-5.03M

2024Q2

5068

795.80M

83.72%

-2.01M

2024Q1

4916

795.04M

83.62%

-6.22M

2023Q4

4670

799.46M

84.21%

-2.37M

2023Q3

4354

800.21M

84.30%

-1.19M

2023Q2

4197

799.48M

84.22%

-4.32M

2023Q1

4061

801.36M

84.15%

-9.39M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Lilly Endowment, Inc.

96.02M

10.13%

-220.00K

-0.23%

Mar 31, 2025

The Vanguard Group, Inc.

78.87M

8.32%

+4.97M

+6.73%

Mar 31, 2025

PNC Investments LLC

51.09M

5.39%

+1.95K

+0.00%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

41.47M

4.38%

+359.58K

+0.87%

Mar 31, 2025

State Street Global Advisors (US)

34.44M

3.63%

+124.04K

+0.36%

Mar 31, 2025

Fidelity Management & Research Company LLC

27.18M

2.87%

-2.17M

-7.40%

Mar 31, 2025

Capital World Investors

18.38M

1.94%

-1.17M

-5.98%

Mar 31, 2025

Geode Capital Management, L.L.C.

18.53M

1.95%

+1.14M

+6.58%

Mar 31, 2025

T. Rowe Price Associates, Inc.

17.98M

1.9%

-1.75M

-8.89%

Mar 31, 2025

Capital Research Global Investors

15.75M

1.66%

+4.99M

+46.39%

Mar 31, 2025

관련 ETF

마지막 업데이트: Wed, Aug 6

이름

비율

Defiance Daily Target 2X Long LLY ETF

84.88%

iShares U.S. Pharmaceuticals ETF

20.57%

Harbor Health Care ETF

16.13%

Roundhill GLP-1 & Weight Loss ETF

15.57%

VanEck Pharmaceutical ETF

13.65%

Amplify Weight Loss Drug & Treatment ETF

12.82%

Proshares Ultra Health Care

12.54%

Health Care Select Sector SPDR Fund

12.53%

iShares U.S. Healthcare ETF

12.33%

Fidelity MSCI Health Care Index ETF

11.06%

Defiance Daily Target 2X Long LLY ETF

비율84.88%

iShares U.S. Pharmaceuticals ETF

비율20.57%

Harbor Health Care ETF

비율16.13%

Roundhill GLP-1 & Weight Loss ETF

비율15.57%

VanEck Pharmaceutical ETF

비율13.65%

Amplify Weight Loss Drug & Treatment ETF

비율12.82%

Proshares Ultra Health Care

비율12.54%

Health Care Select Sector SPDR Fund

비율12.53%

iShares U.S. Healthcare ETF

비율12.33%

Fidelity MSCI Health Care Index ETF

비율11.06%

주식 배당금

지난 5년 동안 총 18.06B USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

Dec 09, 2024

LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 10, 2025

Feb 14, 2025

Oct 28, 2024

LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024

Nov 15, 2024

Dec 10, 2024

Nov 15, 2024

Jun 24, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024

Aug 15, 2024

Sep 10, 2024

Aug 15, 2024

May 06, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024

May 16, 2024

Jun 10, 2024

May 15, 2024

Dec 08, 2023

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024

Feb 15, 2024

Mar 08, 2024

Feb 14, 2024

Nov 01, 2023

LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023

Nov 15, 2023

Dec 08, 2023

Nov 14, 2023

Jun 26, 2023

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023

Aug 15, 2023

Sep 08, 2023

Aug 14, 2023

May 01, 2023

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023

May 15, 2023

Jun 09, 2023

May 12, 2023

Dec 12, 2022

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 10, 2023

Feb 14, 2023

Oct 17, 2022

LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022

Nov 15, 2022

Dec 09, 2022

Nov 14, 2022

주식 분할

날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

639.440USD

Eli Lilly and Co

639.440

개요

회사

금융